By using DiabetesTimes.co.uk, you agree to our terms and use of cookies to enhance your experience.

Antibiotic duration for diabetic foot infections explored

By Editor
28th January 2019
Footcare, Research

A study to find the most appropriate duration of antibiotic therapy for diabetic foot infections (DFIs) has taken place.

But the analysis, carried out by the University of Geneva, found “no threshold for the optimal duration or route of administration of antibiotic therapy to prevent recurrences” of DFI.

The researchers say the limited data might support “possibly shorter treatment duration for patients” with DFI.

The findings, published by the journal Diabetes, Obesity and Metabolism, investigated 1,018 DFI episodes in 482 people with diabetes.

A clinical pathway for adult patients with DFIs (retrospective cohort analysis) was used to create a cluster‐controlled Cox regression model to assess factors related to remission of infection, emphasising antibiotic‐related variables. Total amputations as a result of DFI and DFI episodes with a follow‐up time of <2 months were excluded.

Summarising the results, the researchers said: “We identified 392 episodes of osteomyelitis, 626 soft tissue infections, 246 large abscesses, 322 episodes of cellulitis and 335 episodes of necrosis; 313 cases involved revascularisation. Patients underwent surgical debridement for 824 episodes (81%), of which 596 (59%) required amputation. The median total duration of antibiotic therapy was 20 days. After a median follow‐up of 3 years, 251 of the episodes (24.7%) were followed by ≥1 additional episode(s). Comparing patients with and without additional episodes, risk of recurrence was lower in those who underwent amputation, had type 1 diabetes, or underwent revascularization.

“On multivariate analysis including the entire study population, risk of remission was inversely associated with type 1 diabetes (hazard ratio [HR] 0.3, 95% confidence interval [CI] 0.2‐0.6). Neither duration of antibiotic therapy nor parenteral treatment affected risk of recurrence (HR 1.0, 95% CI 0.99‐1.01 for both). Similarly, neither >3 weeks versus <3 weeks of therapy, nor >1 week versus <1 week of intravenous treatment affected recurrence.

“In stratified analyses for both soft tissue DFIs or osteomyelitis separately, we did not observe associations of antibiotic duration with microbiological or clinical recurrences of DFI. The HRs were 1.0 (95% CI 0.6‐1.8) for an antibiotic duration >3 weeks overall and 0.6 (95% CI 0.2‐1.3) for osteomyelitis cases only. Plotting of duration of antibiotic therapy failed to identify any optimal threshold for preventing recurrences.”

To access the study, click here.

Picture credit: Imani Clovis

Comments (0)

Register an account or login to comment